Therefore, many of the current efforts are focusing on the pharmacological inhibition of upstream JAK kinases in the JAK/Stat pathway, including a phase I clinical trial with the JAK inhibitor WP1066 (NCT01904123), although it should be noted that non-receptor tyrosine kinases such as bone marrow and X-linked (BMX) and members of the Src family can bypass JAK-dependent activation of STAT3 in GBM [9,67]. Here, BMX is linked to glioblastoma.